Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 15/20 | 0.51 |
| ▸ | MAOA | P21397 | 4/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18106017 | 0.97 | MAOB (0.49) | MAOBMAOAMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL18105989 | 0.97 | MAOB (0.49) | MAOBMAOAMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL18106019 | 0.97 | MAOB (0.49) | MAOBMAOAMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL18105797 | 0.97 | MAOB (0.49) | MAOBMAOAMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL18106016 | 0.97 | MAOB (0.49) | MAOBMAOAMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL18105888 | 0.91 | MAOB (0.49) | MAOBMAOAMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL6665880 | 0.88 | MAOB (0.58) | MAOBMAOAMRGPRX4ALDH1A1NPSR1 | |
| SCHEMBL18105950 | 0.88 | MAOB (0.47) | MAOBMAOAMRGPRX4CYP4F2CYP4A11 | |
| SCHEMBL11427053 | 0.85 | ALDH1A1 (0.57) | MRGPRX4ALDH1A1NPSR1 | |
| SCHEMBL5277923 | 0.84 | CYP4F2 (0.68) | MRGPRX4CYP4F2CYP4A11SLC7A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567442-B | Inhibitors of hepatitis C virus polymerase | 共晶制药公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3274340-B1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA INC (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3274340-B1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA INC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2018-02-22 | — | — | US | disclosed |
| WO-2016154241-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | MAOB 248/4885MAOA 221/4885MRGPRX4 3495/4885 |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | POLI, POLR2E, POLR2H | MAOB 248/4885MAOA 221/4885MRGPRX4 3495/4885 |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | POLI, POLR2E, POLR2H | MAOB 248/4885MAOA 221/4885MRGPRX4 3495/4885 |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | MAOB 248/4885MAOA 221/4885MRGPRX4 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.